Identifying cancer promotion signals to improve prevention strategies
Official title: PROMINENT: Discovering the molecular signatures of cancer PROMotion to INform prevENTion
Funded at Imperial College of Science, Technology and Medicine · NIH-10912837 · Data updated 2026-11-12
This study is looking at the tiny changes in our cells that can lead to cancer, hoping to find clues that help us prevent it, so that patients can get personalized advice on how to lower their risk based on their unique biology.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Imperial College of Science, Technology and Medicine NIH-funded |
| Lab location | 1 site (London, United Kingdom) |
| Project start | August 23, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $107,654 |
| NIH project number | 1OT2CA290880-01 |
| Project ID | NIH-10912837 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for cancer due to genetic, environmental, or lifestyle factors.
✕Less likely to help
Patients who are not at risk for cancer or those with established cancer diagnoses may not receive benefit from this research.
What this research studies
This research investigates the molecular signatures that contribute to the promotion of cancer, aiming to uncover specific biological markers that can inform prevention strategies. By analyzing various biological samples, the research seeks to understand how these molecular signatures influence cancer development. Patients may benefit from this research as it could lead to more targeted prevention measures based on individual risk factors identified through these signatures.
Why it matters
Potential benefit: If successful, this research could provide patients with personalized prevention strategies that significantly reduce their risk of developing cancer.
How similar studies have gone: Previous research has shown promise in identifying molecular signatures related to cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Imperial College of Science, Technology and Medicine
London, United Kingdom Active
Researchers
- Principal investigator: Gunter, Marc James — Imperial College of Science, Technology and Medicine
- Study coordinator: Gunter, Marc James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.